Hjem › Sklerodermi › South Carolina › Charleston
Sklerodermi kliniske forsøg i Charleston, SC
4 studier for Sklerodermi søger deltagere på steder i og omkring Charleston (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RekruttererFase 1
- Medical University of South Carolina, Charleston
Platform Clinical Study for Conquering Scleroderma
RekruttererFase 2
- Medical University of South Carolina (MUSC), Charleston
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RekruttererFase 2
- Artiva Investigational Site Charleston, Charleston
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
RekruttererFase 2
- aTyr Investigative Site, Charleston
Sklerodermi forsøg i andre byer
- New York City, NY11 studier
- Ann Arbor, MI10 studier
- Chicago, IL10 studier
- Houston, TX9 studier
- Boston, MA7 studier
- Durham, NC7 studier
- Los Angeles, CA7 studier
- New Orleans, LA6 studier
- Philadelphia, PA6 studier
- Baltimore, MD6 studier
- Dallas, TX5 studier
- Pittsburgh, PA5 studier
Andre studier i Charleston
- Depression19 studier
- Slagtilfælde18 studier
- Hjertesvigt18 studier
- Posttraumatisk stresslidelse16 studier
- Ikke-småcellet lungecancer16 studier
- Prostatakræft15 studier
- Kardiovaskulær sygdom15 studier
- Pladecellekræft i hoved og hals14 studier
- Kræft (alle typer)14 studier
- Parkinsons sygdom13 studier
- Interstitielle lungesygdomme13 studier
- Brystkræft12 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.